OLMA vs. CALT, ETNB, OCUL, AMPH, BGM, AUPH, WVE, GYRE, PAHC, and MLYS
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Ocular Therapeutix (OCUL), Amphastar Pharmaceuticals (AMPH), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs.
Olema Pharmaceuticals (NASDAQ:OLMA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
Olema Pharmaceuticals received 12 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.22% of users gave Olema Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Olema Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Olema Pharmaceuticals' return on equity of -53.56% beat Calliditas Therapeutics AB (publ)'s return on equity.
Olema Pharmaceuticals has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Olema Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Olema Pharmaceuticals had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Olema Pharmaceuticals' average media sentiment score of 0.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Olema Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 374.81%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).
Summary
Olema Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 5/23/2025 by MarketBeat.com Staff
